Searching for Solutions

This new proceedings of a workshop summarizes emerging scientific insights into brain-body communication pathways, and the implications for therapeutic development, public health, and overall well-being.

BPS received a petition to recognize Pharmacogenomics as a BPS specialty certification and has opened the public comment period. The comment period will close on June 3, 2026 at 5:00 PM ET.

Sometime in your career, you'll have to say no. Read more from Dr. Andrea Beall about how to professionally say "no" while leaving opportunities open for the future.

This paper is part of the Technical Assistance Coalition’s Refocus and Renew: Moving Towards Health series—a 10-paper collection guiding state leaders on SMI and SED treatment, recovery, and whole-person health.

In our newest member profile showcasing psychiatric pharmacist impact, learn how Dr. Jacky Parizher works as an outreach pharmacist providing low barrier treatment for opioid use disorder.

AAPP's newest member profile showcases psychiatric pharmacist impact through low barrier outreach showcasing how pharmacists can deliver medications and  psychiatric and substance use disorder care to underserved individuals.

The findings of this study suggest no increased risk of long term adverse neurodevelopmental outcomes among children with prenatal exposure to buprenorphine versus methadone, further supporting buprenorphine as a safe treatment option for opioid use disorder during pregnancy.

Evidence suggests that the use of nicotine-containing e-cigarettes supports cigarette smoking cessation and reduction among individuals who smoke cigarettes regularly.

Joinpoint regression was used to examine mortality rates for opioid-only, opioids with a stimulant, opioids with benzodiazepines, among racial/gender groups to measure temporal trends in age-adjusted overdose mortality due to polysubstance-related overdose.

In this case series, researchers describe outpatient DTI outcomes.

This series of papers calls on state leaders to refocus on serious mental illness and serious emotional disturbances treatment and recovery and focuses on providing updated information and guidance on SMI and SED and renewing efforts for systems-level changes.

The Substance Abuse and Mental Health Services Administration (SAMHSA) expanded its list of prohibited harm reduction services to exclude drug testing strips in new guidance documents. The updated guidance prohibits test kits that can be used to test for the presence of fentanyl or xylazine in drugs, which were explicitly allowed in a July letter.

In this cross-sectional study using contemporary data and methods, post-2018 Medicaid expansions were associated with substantial increases in buprenorphine treatment, particularly in high-need states operating under newer prescribing regulations.

A qualitative study of adults aged 65 and older in Southern California found that older medical cannabis users reported frequent and chronic use, widespread self-experimentation due to a lack of clinical guidance, and substitution of cannabis for other medications.

These results indicate the potential of PrR to capture gradual improvements in quality of life and reflect recovery progress.

A survey of U.S. behavioral health agency officials from every state and the District of Columbia.

Alcohol and drug addiction can cause many harms. This Research in Context feature looks at research into the causes of addiction and new ways to treat it.

Findings highlight the importance of policy and funding mechanisms to ensure the long-term viability of MHUs.

Person-level characteristics were particularly strong in predicting motivation for and perceived access to daily nondrug rewards.

This study conducted a ‘mega-analysis’ integrating 11 independent resting-state functional magnetic resonance imaging datasets across five psychedelic drugs from research groups spanning three continents and five countries.

BPS is requesting applicants to serve as examination item writers for the specialty certification in Psychiatric Pharmacy (BCPP) examination. If selected, your participation will consist of access to virtual training materials, as well as access to a web-based item authoring platform to draft and submit 5-10 exam items according to assigned areas of the examination content outline beginning in late May 2026. Applications are due May 2, 2026.

AAPP joined ASHP and partnering pharmacy organizations expressing concerns about the recently revised charter for the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). In our joint statement, we offer key considerations to restore patient and healthcare provider confidence that the nation's vaccine recommendation advisory framework is credible, independent, and scientifically grounded.

There is some evidence that dialectical behavioral/acceptance and commitment therapies, contingency management alone or with cognitive-behavioral therapy with motivation enhancement, N-acetylcysteine, cannabidiol or varenicline may facilitate abstinence, reduce use and/or support treatment completion for cannabis use disorder.

These findings highlight an increased prevalence of internet addiction among adolescents, which is linked to increased levels of depression, anxiety and a lower quality of life.

Even after accounting for correlated variables, onset of cannabis use during early adolescence is associated with increased likelihood of OUD and riskier forms of opioid use that increase vulnerability to overdose and mortality.